PMC:7461420 / 94630-95717 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T343","span":{"begin":157,"end":162},"obj":"Body_part"}],"attributes":[{"id":"A343","pred":"fma_id","subj":"T343","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Among them two approved drugs, niclosamide (181) and ciclesonide (182; Figure 39), exhibited notable inhibitory activities against virus replication in Vero cells. Niclosamide exhibited very potent antiviral activity against SARS‐CoV‐2 (IC50, 0.28 µM). The action of niclosamide might be attributed to autophagy as it was reported for MERS‐CoV. 239 Ciclesonide (182; Figure 39) is another interesting drug candidate with far lower antiviral potency (IC50, 4.33 µM) compared to niclosamide. It is a cortisol derivative used to treat asthma and allergic rhinitis. 241 A recent report by Matsuyama et al. confirmed ciclesonide as a possible antiviral drug against SARS‐CoV‐2. 242 A treatment report of three COVID‐19 patients (https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/) merits further clinical investigation of this drug. The molecular target of ciclesonide's antiviral activity was revealed to be NSP15, a viral riboendonuclease. Together with its well‐established anti‐inflammatory effects, ciclesonide could offer an interesting option for the control of COVID‐19 symptoms."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T445","span":{"begin":225,"end":229},"obj":"Disease"},{"id":"T446","span":{"begin":533,"end":539},"obj":"Disease"},{"id":"T447","span":{"begin":544,"end":561},"obj":"Disease"},{"id":"T448","span":{"begin":544,"end":552},"obj":"Disease"},{"id":"T449","span":{"begin":553,"end":561},"obj":"Disease"},{"id":"T450","span":{"begin":663,"end":667},"obj":"Disease"},{"id":"T451","span":{"begin":708,"end":716},"obj":"Disease"},{"id":"T452","span":{"begin":1069,"end":1077},"obj":"Disease"}],"attributes":[{"id":"A445","pred":"mondo_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A446","pred":"mondo_id","subj":"T446","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A447","pred":"mondo_id","subj":"T447","obj":"http://purl.obolibrary.org/obo/MONDO_0011786"},{"id":"A448","pred":"mondo_id","subj":"T448","obj":"http://purl.obolibrary.org/obo/MONDO_0004980"},{"id":"A449","pred":"mondo_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/MONDO_0003014"},{"id":"A450","pred":"mondo_id","subj":"T450","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A451","pred":"mondo_id","subj":"T451","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A452","pred":"mondo_id","subj":"T452","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Among them two approved drugs, niclosamide (181) and ciclesonide (182; Figure 39), exhibited notable inhibitory activities against virus replication in Vero cells. Niclosamide exhibited very potent antiviral activity against SARS‐CoV‐2 (IC50, 0.28 µM). The action of niclosamide might be attributed to autophagy as it was reported for MERS‐CoV. 239 Ciclesonide (182; Figure 39) is another interesting drug candidate with far lower antiviral potency (IC50, 4.33 µM) compared to niclosamide. It is a cortisol derivative used to treat asthma and allergic rhinitis. 241 A recent report by Matsuyama et al. confirmed ciclesonide as a possible antiviral drug against SARS‐CoV‐2. 242 A treatment report of three COVID‐19 patients (https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/) merits further clinical investigation of this drug. The molecular target of ciclesonide's antiviral activity was revealed to be NSP15, a viral riboendonuclease. Together with its well‐established anti‐inflammatory effects, ciclesonide could offer an interesting option for the control of COVID‐19 symptoms."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1058","span":{"begin":44,"end":47},"obj":"http://purl.obolibrary.org/obo/CLO_0054057"},{"id":"T1059","span":{"begin":112,"end":122},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1060","span":{"begin":131,"end":136},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T1061","span":{"begin":152,"end":156},"obj":"http://purl.obolibrary.org/obo/CLO_0009524"},{"id":"T1062","span":{"begin":152,"end":156},"obj":"http://purl.obolibrary.org/obo/CLO_0050515"},{"id":"T1063","span":{"begin":157,"end":162},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T1064","span":{"begin":208,"end":216},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1065","span":{"begin":497,"end":498},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1066","span":{"begin":568,"end":569},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1067","span":{"begin":629,"end":630},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1068","span":{"begin":680,"end":681},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1069","span":{"begin":759,"end":761},"obj":"http://purl.obolibrary.org/obo/CLO_0037161"},{"id":"T1070","span":{"begin":881,"end":889},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1071","span":{"begin":916,"end":917},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Among them two approved drugs, niclosamide (181) and ciclesonide (182; Figure 39), exhibited notable inhibitory activities against virus replication in Vero cells. Niclosamide exhibited very potent antiviral activity against SARS‐CoV‐2 (IC50, 0.28 µM). The action of niclosamide might be attributed to autophagy as it was reported for MERS‐CoV. 239 Ciclesonide (182; Figure 39) is another interesting drug candidate with far lower antiviral potency (IC50, 4.33 µM) compared to niclosamide. It is a cortisol derivative used to treat asthma and allergic rhinitis. 241 A recent report by Matsuyama et al. confirmed ciclesonide as a possible antiviral drug against SARS‐CoV‐2. 242 A treatment report of three COVID‐19 patients (https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/) merits further clinical investigation of this drug. The molecular target of ciclesonide's antiviral activity was revealed to be NSP15, a viral riboendonuclease. Together with its well‐established anti‐inflammatory effects, ciclesonide could offer an interesting option for the control of COVID‐19 symptoms."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T703","span":{"begin":24,"end":29},"obj":"Chemical"},{"id":"T704","span":{"begin":164,"end":175},"obj":"Chemical"},{"id":"T705","span":{"begin":198,"end":207},"obj":"Chemical"},{"id":"T706","span":{"begin":350,"end":361},"obj":"Chemical"},{"id":"T707","span":{"begin":402,"end":406},"obj":"Chemical"},{"id":"T708","span":{"begin":432,"end":441},"obj":"Chemical"},{"id":"T709","span":{"begin":499,"end":507},"obj":"Chemical"},{"id":"T710","span":{"begin":640,"end":654},"obj":"Chemical"},{"id":"T711","span":{"begin":640,"end":649},"obj":"Chemical"},{"id":"T712","span":{"begin":650,"end":654},"obj":"Chemical"},{"id":"T713","span":{"begin":759,"end":761},"obj":"Chemical"},{"id":"T714","span":{"begin":827,"end":831},"obj":"Chemical"},{"id":"T715","span":{"begin":871,"end":880},"obj":"Chemical"}],"attributes":[{"id":"A703","pred":"chebi_id","subj":"T703","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A704","pred":"chebi_id","subj":"T704","obj":"http://purl.obolibrary.org/obo/CHEBI_7553"},{"id":"A705","pred":"chebi_id","subj":"T705","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A706","pred":"chebi_id","subj":"T706","obj":"http://purl.obolibrary.org/obo/CHEBI_31397"},{"id":"A707","pred":"chebi_id","subj":"T707","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A708","pred":"chebi_id","subj":"T708","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A709","pred":"chebi_id","subj":"T709","obj":"http://purl.obolibrary.org/obo/CHEBI_17650"},{"id":"A710","pred":"chebi_id","subj":"T710","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A711","pred":"chebi_id","subj":"T711","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A712","pred":"chebi_id","subj":"T712","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A713","pred":"chebi_id","subj":"T713","obj":"http://purl.obolibrary.org/obo/CHEBI_30347"},{"id":"A714","pred":"chebi_id","subj":"T714","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A715","pred":"chebi_id","subj":"T715","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Among them two approved drugs, niclosamide (181) and ciclesonide (182; Figure 39), exhibited notable inhibitory activities against virus replication in Vero cells. Niclosamide exhibited very potent antiviral activity against SARS‐CoV‐2 (IC50, 0.28 µM). The action of niclosamide might be attributed to autophagy as it was reported for MERS‐CoV. 239 Ciclesonide (182; Figure 39) is another interesting drug candidate with far lower antiviral potency (IC50, 4.33 µM) compared to niclosamide. It is a cortisol derivative used to treat asthma and allergic rhinitis. 241 A recent report by Matsuyama et al. confirmed ciclesonide as a possible antiviral drug against SARS‐CoV‐2. 242 A treatment report of three COVID‐19 patients (https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/) merits further clinical investigation of this drug. The molecular target of ciclesonide's antiviral activity was revealed to be NSP15, a viral riboendonuclease. Together with its well‐established anti‐inflammatory effects, ciclesonide could offer an interesting option for the control of COVID‐19 symptoms."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T126","span":{"begin":302,"end":311},"obj":"http://purl.obolibrary.org/obo/GO_0016236"},{"id":"T127","span":{"begin":302,"end":311},"obj":"http://purl.obolibrary.org/obo/GO_0006914"}],"text":"Among them two approved drugs, niclosamide (181) and ciclesonide (182; Figure 39), exhibited notable inhibitory activities against virus replication in Vero cells. Niclosamide exhibited very potent antiviral activity against SARS‐CoV‐2 (IC50, 0.28 µM). The action of niclosamide might be attributed to autophagy as it was reported for MERS‐CoV. 239 Ciclesonide (182; Figure 39) is another interesting drug candidate with far lower antiviral potency (IC50, 4.33 µM) compared to niclosamide. It is a cortisol derivative used to treat asthma and allergic rhinitis. 241 A recent report by Matsuyama et al. confirmed ciclesonide as a possible antiviral drug against SARS‐CoV‐2. 242 A treatment report of three COVID‐19 patients (https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/) merits further clinical investigation of this drug. The molecular target of ciclesonide's antiviral activity was revealed to be NSP15, a viral riboendonuclease. Together with its well‐established anti‐inflammatory effects, ciclesonide could offer an interesting option for the control of COVID‐19 symptoms."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T21","span":{"begin":533,"end":539},"obj":"Phenotype"},{"id":"T22","span":{"begin":544,"end":561},"obj":"Phenotype"}],"attributes":[{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0002099"},{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0003193"}],"text":"Among them two approved drugs, niclosamide (181) and ciclesonide (182; Figure 39), exhibited notable inhibitory activities against virus replication in Vero cells. Niclosamide exhibited very potent antiviral activity against SARS‐CoV‐2 (IC50, 0.28 µM). The action of niclosamide might be attributed to autophagy as it was reported for MERS‐CoV. 239 Ciclesonide (182; Figure 39) is another interesting drug candidate with far lower antiviral potency (IC50, 4.33 µM) compared to niclosamide. It is a cortisol derivative used to treat asthma and allergic rhinitis. 241 A recent report by Matsuyama et al. confirmed ciclesonide as a possible antiviral drug against SARS‐CoV‐2. 242 A treatment report of three COVID‐19 patients (https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/) merits further clinical investigation of this drug. The molecular target of ciclesonide's antiviral activity was revealed to be NSP15, a viral riboendonuclease. Together with its well‐established anti‐inflammatory effects, ciclesonide could offer an interesting option for the control of COVID‐19 symptoms."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2903","span":{"begin":225,"end":235},"obj":"Species"},{"id":"2904","span":{"begin":335,"end":343},"obj":"Species"},{"id":"2905","span":{"begin":663,"end":673},"obj":"Species"},{"id":"2906","span":{"begin":717,"end":725},"obj":"Species"},{"id":"2907","span":{"begin":31,"end":42},"obj":"Chemical"},{"id":"2908","span":{"begin":53,"end":64},"obj":"Chemical"},{"id":"2909","span":{"begin":164,"end":175},"obj":"Chemical"},{"id":"2910","span":{"begin":267,"end":278},"obj":"Chemical"},{"id":"2911","span":{"begin":350,"end":361},"obj":"Chemical"},{"id":"2912","span":{"begin":478,"end":489},"obj":"Chemical"},{"id":"2913","span":{"begin":499,"end":507},"obj":"Chemical"},{"id":"2914","span":{"begin":614,"end":625},"obj":"Chemical"},{"id":"2915","span":{"begin":1004,"end":1015},"obj":"Chemical"},{"id":"2916","span":{"begin":533,"end":539},"obj":"Disease"},{"id":"2917","span":{"begin":544,"end":561},"obj":"Disease"},{"id":"2918","span":{"begin":708,"end":716},"obj":"Disease"},{"id":"2919","span":{"begin":1069,"end":1077},"obj":"Disease"}],"attributes":[{"id":"A2903","pred":"tao:has_database_id","subj":"2903","obj":"Tax:2697049"},{"id":"A2904","pred":"tao:has_database_id","subj":"2904","obj":"Tax:1335626"},{"id":"A2905","pred":"tao:has_database_id","subj":"2905","obj":"Tax:2697049"},{"id":"A2906","pred":"tao:has_database_id","subj":"2906","obj":"Tax:9606"},{"id":"A2907","pred":"tao:has_database_id","subj":"2907","obj":"MESH:D009534"},{"id":"A2908","pred":"tao:has_database_id","subj":"2908","obj":"MESH:C120481"},{"id":"A2909","pred":"tao:has_database_id","subj":"2909","obj":"MESH:D009534"},{"id":"A2910","pred":"tao:has_database_id","subj":"2910","obj":"MESH:D009534"},{"id":"A2911","pred":"tao:has_database_id","subj":"2911","obj":"MESH:C120481"},{"id":"A2912","pred":"tao:has_database_id","subj":"2912","obj":"MESH:D009534"},{"id":"A2913","pred":"tao:has_database_id","subj":"2913","obj":"MESH:D006854"},{"id":"A2914","pred":"tao:has_database_id","subj":"2914","obj":"MESH:C120481"},{"id":"A2915","pred":"tao:has_database_id","subj":"2915","obj":"MESH:C120481"},{"id":"A2916","pred":"tao:has_database_id","subj":"2916","obj":"MESH:D001249"},{"id":"A2917","pred":"tao:has_database_id","subj":"2917","obj":"MESH:D065631"},{"id":"A2918","pred":"tao:has_database_id","subj":"2918","obj":"MESH:C000657245"},{"id":"A2919","pred":"tao:has_database_id","subj":"2919","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Among them two approved drugs, niclosamide (181) and ciclesonide (182; Figure 39), exhibited notable inhibitory activities against virus replication in Vero cells. Niclosamide exhibited very potent antiviral activity against SARS‐CoV‐2 (IC50, 0.28 µM). The action of niclosamide might be attributed to autophagy as it was reported for MERS‐CoV. 239 Ciclesonide (182; Figure 39) is another interesting drug candidate with far lower antiviral potency (IC50, 4.33 µM) compared to niclosamide. It is a cortisol derivative used to treat asthma and allergic rhinitis. 241 A recent report by Matsuyama et al. confirmed ciclesonide as a possible antiviral drug against SARS‐CoV‐2. 242 A treatment report of three COVID‐19 patients (https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/) merits further clinical investigation of this drug. The molecular target of ciclesonide's antiviral activity was revealed to be NSP15, a viral riboendonuclease. Together with its well‐established anti‐inflammatory effects, ciclesonide could offer an interesting option for the control of COVID‐19 symptoms."}

{"project":"LitCovid-sentences","denotations":[{"id":"T840","span":{"begin":0,"end":163},"obj":"Sentence"},{"id":"T841","span":{"begin":164,"end":252},"obj":"Sentence"},{"id":"T842","span":{"begin":253,"end":344},"obj":"Sentence"},{"id":"T843","span":{"begin":345,"end":490},"obj":"Sentence"},{"id":"T844","span":{"begin":491,"end":562},"obj":"Sentence"},{"id":"T845","span":{"begin":563,"end":674},"obj":"Sentence"},{"id":"T846","span":{"begin":675,"end":832},"obj":"Sentence"},{"id":"T847","span":{"begin":833,"end":941},"obj":"Sentence"},{"id":"T848","span":{"begin":942,"end":1087},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Among them two approved drugs, niclosamide (181) and ciclesonide (182; Figure 39), exhibited notable inhibitory activities against virus replication in Vero cells. Niclosamide exhibited very potent antiviral activity against SARS‐CoV‐2 (IC50, 0.28 µM). The action of niclosamide might be attributed to autophagy as it was reported for MERS‐CoV. 239 Ciclesonide (182; Figure 39) is another interesting drug candidate with far lower antiviral potency (IC50, 4.33 µM) compared to niclosamide. It is a cortisol derivative used to treat asthma and allergic rhinitis. 241 A recent report by Matsuyama et al. confirmed ciclesonide as a possible antiviral drug against SARS‐CoV‐2. 242 A treatment report of three COVID‐19 patients (https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/) merits further clinical investigation of this drug. The molecular target of ciclesonide's antiviral activity was revealed to be NSP15, a viral riboendonuclease. Together with its well‐established anti‐inflammatory effects, ciclesonide could offer an interesting option for the control of COVID‐19 symptoms."}